Showing posts with label Liquid Biopsy Market. Show all posts
Showing posts with label Liquid Biopsy Market. Show all posts

Thursday, 21 March 2019

Liquid Biopsy Market Research Report 2018, Opportunities, Share, Size, Revenue, Gross Margin And Its Competitors By 2026

ResearchMoz presents professional and in-depth study of "Liquid Biopsy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026".

Liquid Biopsy Market: Scope and Methodology

This report on the global liquid biopsy market analyzes the current and future prospects of the market. The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails.

Get Free PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1896551

Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global liquid biopsy market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. The report also provides insights into the key trends of the liquid biopsy market such as rise in prevalence of cancer, increasing applications of liquid biopsy, advantages of liquid biopsy over tumor biopsy and improvement in health care infrastructure in emerging economies. Key market indicators influencing the global liquid biopsy market including cost constraints and regulatory landscape have been taken into consideration. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global liquid biopsy market.

Market revenue in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global liquid biopsy market for each segment is also reflected. Additionally, market-related factors such as favorable reimbursement scenario, expanding applications in chronic diseases and historical year-on-year growth have been taken into consideration while estimating the market size.

Liquid Biopsy Market: Segmentation

Based on application, the global liquid biopsy market has been segmented into oncology, NIPT, transplant diagnostics, and others. In terms of circulating biomarkers, the global liquid biopsy market has been classified into circulating tumor cells (CTC), free nucleic acid, and extracellular vesicles (exosomes). In terms of end-user, the market has been segregated into hospitals, reference laboratories, academic and research institutes, and others.

In terms of region, the global liquid biopsy market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been further segmented into major countries in each of the regions. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, Japan, India, Brazil, GCC, South Africa, and Mexico.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/liquid-biopsy-market-global-industry-analysis-size-share-growth-trends-and-forecast-2018-2026-report.html/toc

Liquid Biopsy Market: Competitive Landscape

The report also profiles major players in the liquid biopsy market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Biocept, Inc., MDxHealth, Myriad Genetics, Inc., Bio-Rad Laboratories, QIAGEN, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genomic Health, Inc., and Illumina, Inc.

The global liquid biopsy market has been segmented as follows:

Global Liquid Biopsy Market, by Application

    Oncology
    NIPT
    Transplant Diagnostics
    Others

Global Liquid Biopsy Market, by Circulating Biomarker

    Circulating Tumor Cells (CTC)
    Free Nucleic Acid
    Extracellular vesicles/Exosomes

Global Liquid Biopsy Market, by End-user

    Hospitals
    Reference Laboratories
    Academic and Research Institutes
    Others

 Global Liquid Biopsy Market, by Region

    North America
        U.S.
        Canada
    Europe
        Germany
        U.K.
        France
        Spain
        Italy
        Rest of Europe
    Asia Pacific
        Australia & New Zealand
        Japan
        China
        India
        Rest of Asia pacific

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1896551

    Latin America
        Brazil
        Mexico
        Rest of Latin America
    Middle East & Africa
        GCC
        South Africa
        Israel
        Rest of Middle East & Africa

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Friday, 16 November 2018

Worldwide Technology of Liquid Biopsy Market in Global Industry 2018-2024

ResearchMoz presents professional and in-depth study of "Liquid Biopsy Market, Global Analysis by Cancer (Lung, Breast, Colorectal, etc), Products, Circulating Biomarkers, Sample, Clinical Application, Regions & Companies".

Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1866935

Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.

The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient’s tumor and provide clues about the treatment that a patient’s needs.

Renub Research report titled “Liquid Biopsy Market, Global Analysis by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen)” provides a complete analysis of Global Liquid Biopsy Market.

By Cancer – Lung Cancer Controls the Liquid Biopsy Market

The report studies the market of the following cancer segments: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. Lung cancer and Breast cancer together accounts for the considerable market share in the global liquid biopsy market.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/liquid-biopsy-market-global-analysis-by-cancer-lung-breast-colorectal-etc-products-circulating-biomarkers-sample-clinical-application-regions-companies-report.html/toc

By Product – Majority of Liquid Biopsy Market held by Kits & Consumables

The report studies the market of the following product segments: Kits & consumables, Instruments and Services. More than 90% of liquid biopsy market is comprised by kits & Consumables and Instruments.

By Circulating Biomarkers

    The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) together holds significant market share

By Sample – Plasma/Serum accounts for the maximum market

    In terms of Sample used for liquid biopsy, the global liquid biopsy market has been studied as Plasma/Serum, Urine and Others.

By Clinical Application – Screening Purpose leads the Liquid Biopsy Market

The report studies the market of the following clinical application segments: Monitoring, Prognosis, Theranostics & Screening.

By Region – North America and Europe will drive the Liquid Biopsy Market

North America and Europe together controls the Liquid Biopsy Market. In addition; the report also provides the complete geographical analysis of Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Market.

Companies Analysis

Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics, Inc., Genomic Health, NeoGenomics Laboratories, Qiagen; which has been studied thoroughly in the report.

All the 9 Companies Studied in the Report have been Studied from 3 Points

    Company Overview  
    Product Portfolio
    Financial Insight

This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years.

By Cancer

    Lung Cancer
    Breast Cancer
    Colorectal Cancer
    Prostate Cancer
    Others

By Product

    Kits & Consumables
    Instruments
    Services

By Circulating Biomarkers

    Circulating Tumor Cells (CTCs)
    Circulating Tumor DNA (ctDNA)
    Exosomes

By Sample

    Plasma/Serum
    Urine
    Others

By Clinical Application

    Monitoring
    Prognosis
    Theranostics
    Screening

By Regions

    North America
    Europe
    Asia-Pacific
    Latin America
    Middle East/Africa

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1866935

By Companies

    Thermo Fisher Scientific Inc.
    Roche Diagnostics
    Bio-Rad Laboratories Inc.
    Biocept Inc.
    Biocartis
    Myriad Genetics, Inc.
    Genomic Health
    NeoGenomics Laboratories
    Qiagen

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Monday, 24 September 2018

Trend of Liquid Biopsy Market in Global Industry : Market Share, Insight and Application to 2024

ResearchMoz presents professional and in-depth study of "Liquid Biopsy Market, Global Analysis by Cancer (Lung, Breast, Colorectal, etc), Products, Circulating Biomarkers, Sample, Clinical Application, Regions & Companies".

Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1866935

Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.

The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient’s tumor and provide clues about the treatment that a patient’s needs.

Renub Research report titled “Liquid Biopsy Market, Global Analysis by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen)” provides a complete analysis of Global Liquid Biopsy Market.

By Cancer – Lung Cancer Controls the Liquid Biopsy Market

The report studies the market of the following cancer segments: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. Lung cancer and Breast cancer together accounts for the considerable market share in the global liquid biopsy market.

By Product – Majority of Liquid Biopsy Market held by Kits & Consumables

The report studies the market of the following product segments: Kits & consumables, Instruments and Services. More than 90% of liquid biopsy market is comprised by kits & Consumables and Instruments.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/liquid-biopsy-market-global-analysis-by-cancer-lung-breast-colorectal-etc-products-circulating-biomarkers-sample-clinical-application-regions-companies-report.html/toc

By Circulating Biomarkers

    The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) together holds significant market share

By Sample – Plasma/Serum accounts for the maximum market

    In terms of Sample used for liquid biopsy, the global liquid biopsy market has been studied as Plasma/Serum, Urine and Others.

By Clinical Application – Screening Purpose leads the Liquid Biopsy Market

The report studies the market of the following clinical application segments: Monitoring, Prognosis, Theranostics & Screening.

By Region – North America and Europe will drive the Liquid Biopsy Market

North America and Europe together controls the Liquid Biopsy Market. In addition; the report also provides the complete geographical analysis of Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Market.

Companies Analysis

Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics, Inc., Genomic Health, NeoGenomics Laboratories, Qiagen; which has been studied thoroughly in the report.

All the 9 Companies Studied in the Report have been Studied from 3 Points

    Company Overview  
    Product Portfolio
    Financial Insight

This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years.

By Cancer

    Lung Cancer
    Breast Cancer
    Colorectal Cancer
    Prostate Cancer
    Others

By Product

    Kits & Consumables
    Instruments
    Services

By Circulating Biomarkers

    Circulating Tumor Cells (CTCs)
    Circulating Tumor DNA (ctDNA)
    Exosomes

By Sample

    Plasma/Serum
    Urine
    Others

By Clinical Application

    Monitoring
    Prognosis
    Theranostics
    Screening

By Regions

    North America
    Europe
    Asia-Pacific
    Latin America
    Middle East/Africa

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1866935

By Companies

    Thermo Fisher Scientific Inc.
    Roche Diagnostics
    Bio-Rad Laboratories Inc.
    Biocept Inc.
    Biocartis
    Myriad Genetics, Inc.
    Genomic Health
    NeoGenomics Laboratories
    Qiagen

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/